Literature summary for 3.4.14.5 extracted from

Deacon, C.F.
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes (2007), Expert Opin. Investig. Drugs, 16, 533-545.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	sitagliptin is one-daily, orally active, potent and selective DPP-4 inhibitor, which reduces both fasting and postprandial glucose levels and improves summary measures of beta-cell function to produce clinically meaningful reductions in HbA1c concentrations. Efficiacy as both a monotherapy and in combination with merformin or pioglitazone, without causing weight gain	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	sitagliptin is one-daily, orally active, potent and selective DPP-4 inhibitor, which reduces both fasting and postprandial glucose levels and improves summary measures of beta-cell function to produce clinically meaningful reductions in HbA1c concentrations. Efficiacy as both a monotherapy and in combination with merformin or pioglitazone, without causing weight gain	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase 4	-	Homo sapiens
DPP-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)